[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Liver cancer,Immunotherapy,Biomarkers,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J.-S. Lee<\/b><sup>1<\/sup>, S. Yim<sup>2<\/sup>, S.-W. Baek<sup>3<\/sup>, S. Lee<sup>4<\/sup>, B. Sohn<sup>1<\/sup>, Y. Jeong<sup>1<\/sup>, S. Kang<sup>5<\/sup>, K. Park<sup>6<\/sup>, H. Park<sup>1<\/sup>, S. S. Lee<sup>1<\/sup>, A. O. Kaseb<sup>1<\/sup>, J. Kim<sup>5<\/sup>, I.-S. Chu<sup>7<\/sup>; <br\/><sup>1<\/sup>UT MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Korea University College of Medicine, Seoul, Korea, Republic of, <sup>3<\/sup>Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea, Republic of, <sup>4<\/sup>CHA Bundang Medical Center, Seongnam, Korea, Republic of, <sup>5<\/sup>Korea University Guro Hospital, Seoul, Korea, Republic of, <sup>6<\/sup>Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of, <sup>7<\/sup>Bioneer Corporation, Daejeon, Korea, Republic of","CSlideId":"","ControlKey":"419dc111-5a1e-41ca-bd6e-de94ffa31fef","ControlNumber":"9547","DisclosureBlock":"&nbsp;<b>J. Lee, <\/b> None..<br><b>S. Yim, <\/b> None..<br><b>S. Baek, <\/b> None..<br><b>S. Lee, <\/b> None..<br><b>B. Sohn, <\/b> None..<br><b>Y. Jeong, <\/b> None..<br><b>S. Kang, <\/b> None..<br><b>K. Park, <\/b> None..<br><b>H. Park, <\/b> None..<br><b>S. S. Lee, <\/b> None..<br><b>A. O. Kaseb, <\/b> None..<br><b>J. Kim, <\/b> None..<br><b>I. Chu, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10382","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB090","PresenterBiography":"","PresenterDisplayName":"Ju-Seog Lee, PhD","PresenterKey":"f50bad03-0a98-4957-b330-d9c06c008eb6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB090. Predictive genomic biomarkers for atezolizumab plus bevacizumab combination immunotherapy response in liver cancer: Insights from the IMbrave150 trial","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Predictive genomic biomarkers for atezolizumab plus bevacizumab combination immunotherapy response in liver cancer: Insights from the IMbrave150 trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Bladder cancer,Immune checkpoint blockade,Precision medicine,Bioinformatics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S.-W. Baek<\/b><sup>1<\/sup>, S.-K. Kim<sup>1<\/sup>, S.-H. Leem<sup>2<\/sup>, I.-S. Chu<sup>3<\/sup>; <br\/><sup>1<\/sup>Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea, Republic of, <sup>2<\/sup>Dong-A University, Busan, Korea, Republic of, <sup>3<\/sup>Bioneer Corporation, Daejeon, Korea, Republic of","CSlideId":"","ControlKey":"4a23ae17-7f43-4aab-912e-50ad3686f9ed","ControlNumber":"9795","DisclosureBlock":"&nbsp;<b>S. Baek, <\/b> None..<br><b>S. Kim, <\/b> None..<br><b>S. Leem, <\/b> None..<br><b>I. Chu, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10383","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB091","PresenterBiography":null,"PresenterDisplayName":"Seung-Woo Baek, PhD","PresenterKey":"3f364b7f-ad10-43f4-a61f-e85ef33d7f52","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB091. A multigene signature for immunotherapy in patients with high risk non-muscle-invasive bladder cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A multigene signature for immunotherapy in patients with high risk non-muscle-invasive bladder cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Diffuse large B-cell lymphoma,Gene expression,Adoptive cell therapy,Predictive biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Tian<\/b><sup>1<\/sup>, J. Budka<sup>1<\/sup>, F. L. Locke<sup>2<\/sup>, J. R. Westin<sup>3<\/sup>, C. To<sup>1<\/sup>, S. Shahani<sup>1<\/sup>, D. Bedognetti<sup>1<\/sup>, R. R. Shen<sup>1<\/sup>, J. Andrade<sup>1<\/sup>, S. Filosto<sup>1<\/sup>; <br\/><sup>1<\/sup>Kite, a Gilead Company, Santa Monica, CA, <sup>2<\/sup>Moffitt Cancer Center, Tampa, FL, <sup>3<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"720d4ee6-bc0e-41fb-a7f7-b83588ad2eab","ControlNumber":"10245","DisclosureBlock":"<b>&nbsp;Y. Tian, <\/b> <br><b>Kite, a Gilead Company<\/b> Employment. <br><b>J. Budka, <\/b> <br><b>Kite, a Gilead Company<\/b> Employment, Stock, Stock Option, Other Business Ownership, Travel, Other, Accommodations & Expenses. <br><b>F. L. Locke, <\/b> <br><b>A2, Allogene, Amgen, bluebird bio, Bristol Myers Squibb\/Celgene, Calibr, Caribou Biosciences, Cellular Biomedicine Group, Cowen, Daiichi Sankyo, EcoR1, Emerging Therapy Solutions<\/b> Other, Scientific advisory role\/consulting role. <br><b>GammaDelta Therapeutics, Gerson Lehrman Group (GLG), Iovance, Kite, a Gilead Company, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen, Umoja<\/b> Other, Scientific advisory role\/consulting role. <br><b>A2 Bio<\/b> Patent, Other Intellectual Property, Patents, Royalties, other intellectual property in several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy. <br><b>Allogene (Institutional), Aptitude Health, ASH, bluebird bio (Institutional), BioPharma Communications CARE Education, Bristol Myers Squibb (Institutional), CERo Therapeutics (Institutional)<\/b> Other Intellectual Property, Other, Other relationships(Institutional). <br><b>Clinical Care Options Oncology, Imedex, Kite (Institutional), Novartis (Institutional), National Cancer Institute, Leukemia and Lymphoma Society, and Society for Immunotherapy of Cancer<\/b> Other Intellectual Property, Other, Other relationships(Institutional). <br><b>J. R. Westin, <\/b> <br><b>Bristol Myers Squibb<\/b> Other, Consulting\/Advisory,Research Funding. <br><b>Genentech<\/b> Other, Consulting\/Advisory,Research Funding. <br><b>Kite, a Gilead Company<\/b> Consulting\/Advisory,Research Funding. <br><b>ADC Therapeutics<\/b> Other, Research Funding. <br><b>AstraZeneca<\/b> Other, Research Funding. <br><b>Calithera<\/b> Other, Research Funding. <br><b>MorphoSys\/Incyte<\/b> Other, Research Funding. <br><b>Novartis<\/b> Other, Research Funding. <br><b>C. To, <\/b> <br><b>Kite, a Gilead Company<\/b> Employment. <br><b>Gilead Sciences<\/b> Stock, Stock Option, Stock or other ownership. <br><b>S. Shahani, <\/b> <br><b>Kite, a Gilead Company<\/b> Employment, Other. <br><b>Gilead Sciences<\/b> Stock, Stock Option, Other, Stock or other ownership. <br><b>Amgen<\/b> Speakers' Bureau. <br><b>D. Bedognetti, <\/b> <br><b>Kite, a Gilead Company<\/b> Employment. <br><b>Gilead Sciences<\/b> Stock, Stock Option, Stock or other ownership. <br><b>Immunomica SRL<\/b> Stock, Stock Option, Other, Stock or other ownership. <br><b>R. R. Shen, <\/b> <br><b>Kite, a Gilead Company<\/b> Employment, Stock, Stock Option, Other, Patents, royalties and other intellectual property. <br><b>Atara<\/b> Other, Patents, royalties and other intellectual property. <br><b>J. Andrade, <\/b> <br><b>Kite, a Gilead Company<\/b> Employment, Other, Leadership role. <br><b>S. Filosto, <\/b> <br><b>Kite, a Gilead Company<\/b> Employment, Stock, Stock Option, Other, Stock or other ownership. <br><b>Tusk Therapeutics<\/b> Other, Patents, royalties, and other intellectual property.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10384","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB092","PresenterBiography":null,"PresenterDisplayName":"Jill DeCarli","PresenterKey":"967f5608-68fa-4574-ae22-dfe4d56ce89c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB092. Novel tumor gene expression signatures predictive of outcome in large B cell lymphoma treated with CAR T cell therapy (axicabtagene ciloleucel)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Novel tumor gene expression signatures predictive of outcome in large B cell lymphoma treated with CAR T cell therapy (axicabtagene ciloleucel)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Breast cancer,Insulin-like growth factor 1 (IGF-1) receptor,Predictive biomarkers,Gene expression profiling,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"C. Godina<sup>1<\/sup>, M. N. Pollak<sup>2<\/sup>, <b>H. Jernström<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Lunds Universitet, Lund, Sweden, <sup>2<\/sup>McGill, Montreal, QC, Canada","CSlideId":"","ControlKey":"90b9fcea-7bf9-409d-9f4f-7e8e49a164f4","ControlNumber":"9537","DisclosureBlock":"&nbsp;<b>C. Godina, <\/b> None..<br><b>M. N. Pollak, <\/b> None..<br><b>H. Jernström, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10385","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB093","PresenterBiography":null,"PresenterDisplayName":"Helena Jernström, PhD","PresenterKey":"1cb929ba-d1bb-4dff-b334-c5364c25db80","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB093. Low <i>IGFBP7<\/i> expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Low <i>IGFBP7<\/i> expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Liquid biopsies,Minimal Residual Disease,Targeted Therapy,Lung Cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Delahaye<\/b><sup>1<\/sup>, A. Casanova<sup>2<\/sup>, E. Clermont-Tarenchon<sup>3<\/sup>, A. Doussine<sup>1<\/sup>, J.-P. Cerapio<sup>1<\/sup>, A. Anton<sup>4<\/sup>, E. Devienne<sup>5<\/sup>, V. Dongay<sup>5<\/sup>, J. Milia<sup>5<\/sup>, G. Favre<sup>6<\/sup>, O. Calvayrac<sup>1<\/sup>, A. Pradines<sup>2<\/sup>, J. Mazieres<sup>7<\/sup>; <br\/><sup>1<\/sup>Cancer Research Center of Toulouse, INSERM UMR1037, CNRS UMR5071, Toulouse III Paul Sabatier University, Toulouse, France, <sup>2<\/sup>Cancer Research Center of Toulouse, INSERM UMR1037, CNRS UMR5071, Toulouse III Paul Sabatier University; Institut Claudius Regaud, IUCT-O, Laboratory of Medical Biology, Toulouse, France, <sup>3<\/sup>Cancer Research Center of Toulouse, INSERM UMR1037, CNRS UMR5071, Toulouse III Paul Sabatier University; Toulouse University Hospital, Thoracic Oncology Department, Toulouse, France, <sup>4<\/sup>Institut Claudius Regaud, IUCT-O, Laboratory of Medical Biology, Toulouse, France, <sup>5<\/sup>Toulouse University Hospital, Thoracic Oncology Department, Toulouse, France, <sup>6<\/sup>Cancer Research Center of Toulouse, INSERM UMR1037, CNRS UMR5071, Toulouse III Paul Sabatier University; Institut Claudius Regaud, IUCT-O, Laboratory of Medical Biology; University Paul Sabatier, Toulouse, France, <sup>7<\/sup>Cancer Research Center of Toulouse, INSERM UMR1037, CNRS UMR5071, Toulouse III Paul Sabatier University; Toulouse University Hospital, Thoracic Oncology Department; University Paul Sabatier, Toulouse, France","CSlideId":"","ControlKey":"e316aa3b-7730-4479-89d1-fd0889b094b7","ControlNumber":"10686","DisclosureBlock":"&nbsp;<b>C. Delahaye, <\/b> None..<br><b>A. Casanova, <\/b> None..<br><b>E. Clermont-Tarenchon, <\/b> None..<br><b>A. Doussine, <\/b> None..<br><b>J. Cerapio, <\/b> None..<br><b>A. Anton, <\/b> None..<br><b>E. Devienne, <\/b> None..<br><b>V. Dongay, <\/b> None..<br><b>J. Milia, <\/b> None..<br><b>G. Favre, <\/b> None..<br><b>O. Calvayrac, <\/b> None..<br><b>A. Pradines, <\/b> None..<br><b>J. Mazieres, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10386","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB094","PresenterBiography":null,"PresenterDisplayName":"Celia Delahaye, PhD","PresenterKey":"2cdea419-a978-4ca8-993a-184c9419512a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB094. Assessment of minimal residual disease in lung cancer patients treated with osimertinib using liquid biopsy","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Assessment of minimal residual disease in lung cancer patients treated with osimertinib using liquid biopsy","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Biomarkers,NSCLC,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"R. T. Evans<sup>1<\/sup>, E. Shapiro<sup>1<\/sup>, E. Gillon-Zhang<sup>1<\/sup>, J. N. Brown<sup>1<\/sup>, C. King<sup>1<\/sup>, C. Kiser<sup>1<\/sup>, M. Rossi<sup>1<\/sup>, D. Davis<sup>2<\/sup>, M. L. Taylor<sup>3<\/sup>, J. Clower<sup>3<\/sup>, J. Yang<sup>2<\/sup>, C. A. Taylor<sup>3<\/sup>, R. W. Snyder<sup>3<\/sup>, <b>W. J. Levin<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Biofidelity, Morrisville, NC, <sup>2<\/sup>Precision for Medicine, Houston, TX, <sup>3<\/sup>Precision for Medicine, Salem, NC","CSlideId":"","ControlKey":"20efe432-ca69-433e-9046-a6d37f8edfd3","ControlNumber":"10280","DisclosureBlock":"<b>&nbsp;R. T. Evans, <\/b> <br><b>Biofidelity<\/b> Employment, Stock. <br><b>E. Shapiro, <\/b> <br><b>Biofidelity<\/b> Employment, Stock. <br><b>E. Gillon-Zhang, <\/b> <br><b>BIofidelity<\/b> Employment, Stock. <br><b>J. N. Brown, <\/b> <br><b>Biofidelity<\/b> Employment, Stock. <br><b>C. King, <\/b> <br><b>Biofidelity<\/b> Employment, Stock. <br><b>C. Kiser, <\/b> <br><b>Biofidelity<\/b> Employment, Stock. <br><b>M. Rossi, <\/b> <br><b>Biofidelity<\/b> Employment, Stock. <br><b>D. Davis, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>M. L. Taylor, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>J. Clower, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>J. Yang, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>C. A. Taylor, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>R. W. Snyder, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>W. J. Levin, <\/b> <br><b>Biofidelity<\/b> Independent Contractor, Stock, Stock Option.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10387","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB095","PresenterBiography":null,"PresenterDisplayName":"Wendy Levin, MD,MS","PresenterKey":"aad4cc5c-92cc-4d76-8f61-4d1f2bc040d6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB095. ASPYRE-Lung addresses critical gaps in NGS-based biomarker testing: Robust variant calling from NGS QC fails","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"ASPYRE-Lung addresses critical gaps in NGS-based biomarker testing: Robust variant calling from NGS QC fails","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-01 Biomarkers predictive of therapeutic benefit,,"},{"Key":"Keywords","Value":"Telomeres,Therapy Response,Ovarian cancer,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K. Tomasova<\/b><sup>1<\/sup>, K. Seborova<sup>2<\/sup>, M. Kroupa<sup>1<\/sup>, J. Horak<sup>1<\/sup>, L. Vodickova<sup>1<\/sup>, L. Rob<sup>3<\/sup>, M. Hruda<sup>3<\/sup>, M. Mrhalova<sup>4<\/sup>, A. Bartakova<sup>5<\/sup>, J. Bouda<sup>5<\/sup>, T. Fleischer<sup>6<\/sup>, V. N. Kristensen<sup>7<\/sup>, P. Vodicka<sup>1<\/sup>, R. Vaclavikova<sup>2<\/sup>; <br\/><sup>1<\/sup>Institute of Experimental Medicine of the CAS, Prague, Czech Republic, <sup>2<\/sup>National Institute of Public Health, Prague, Czech Republic, <sup>3<\/sup>Charles University, Third Faculty of Medicine, Prague, Czech Republic, <sup>4<\/sup>Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic, <sup>5<\/sup>Charles University, Faculty of Medicine and University Hospital in Pilsen, Pilsen, Czech Republic, <sup>6<\/sup>Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway, <sup>7<\/sup>University of Oslo, Faculty of Medicine, Oslo, Norway","CSlideId":"","ControlKey":"6b67f9e6-0892-4611-8397-3ad62a8a2ba0","ControlNumber":"10359","DisclosureBlock":"&nbsp;<b>K. Tomasova, <\/b> None..<br><b>K. Seborova, <\/b> None..<br><b>M. Kroupa, <\/b> None..<br><b>J. Horak, <\/b> None..<br><b>L. Vodickova, <\/b> None..<br><b>L. Rob, <\/b> None..<br><b>M. Hruda, <\/b> None..<br><b>M. Mrhalova, <\/b> None..<br><b>A. Bartakova, <\/b> None..<br><b>J. Bouda, <\/b> None..<br><b>T. Fleischer, <\/b> None..<br><b>V. N. Kristensen, <\/b> None..<br><b>P. Vodicka, <\/b> None..<br><b>R. Vaclavikova, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10388","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB096","PresenterBiography":"","PresenterDisplayName":"Kristyna Tomasova, MS","PresenterKey":"53966806-a77d-430f-ab60-3daaba9eb91c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB096. Telomere length as a predictor of therapy response and survival in patients diagnosed with ovarian carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Telomere length as a predictor of therapy response and survival in patients diagnosed with ovarian carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-02 Diagnostic biomarkers,,"},{"Key":"Keywords","Value":"Brain\/central nervous system cancers,Biomarkers,DNA,Diagnostic marker,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. B. Douville<\/b>, C. Bettegowda; <br\/>Johns Hopkins University, Baltimore, MD","CSlideId":"","ControlKey":"8355cba3-d186-422f-8f34-ca7f14e69f31","ControlNumber":"10786","DisclosureBlock":"<b>&nbsp;C. B. Douville, <\/b> <br><b>Exact Sciences<\/b> Independent Contractor, Stock Option, Travel, Patent. <br><b>Belay Diagnostics<\/b> Independent Contractor, Stock Option, Other Business Ownership, Grant\/Contract, Travel. <br><b>C. Bettegowda, <\/b> <br><b>Belay Diagnostics<\/b> Fiduciary Officer, Stock.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10389","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB097","PresenterBiography":null,"PresenterDisplayName":"Christopher Douville, BS;PhD","PresenterKey":"db14c893-7df5-4c76-afec-65d34c753a58","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB097. Sensitive detection of central nervous system tumors using a sequencing based cerebrospinal fluid test","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Sensitive detection of central nervous system tumors using a sequencing based cerebrospinal fluid test","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-02 Diagnostic biomarkers,,"},{"Key":"Keywords","Value":"Ovarian cancer,Biomarkers,Proteomics,RNA sequencing (RNA-Seq),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Enroth<sup>1<\/sup>, <b>M. Moskov<\/b><sup>1<\/sup>, J. Lindberg Hedlund<sup>1<\/sup>, S. Popova<sup>2<\/sup>, S. K. G. Forsberg<sup>3<\/sup>, K. Diamanti<sup>3<\/sup>, M. Lycke<sup>4<\/sup>, E. Ivansson<sup>1<\/sup>, A. Tolf<sup>2<\/sup>, K. Sundfeldt<sup>4<\/sup>, K. Stålberg<sup>5<\/sup>, U. Gyllensten<sup>1<\/sup>; <br\/><sup>1<\/sup>Uppsala University, Dept of Immunology, Genetics and Pathology, Uppsala, Sweden, <sup>2<\/sup>Department of Clinical Pathology, Akademiska University Hospital, Uppsala, Sweden, Uppsala, Sweden, <sup>3<\/sup>Olink Proteomics AB, Uppsala, Sweden, <sup>4<\/sup>Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, SE-41685 Gothenburg, Sweden, Göteborg, Sweden, <sup>5<\/sup>Department of Women’s and Children’s Health, Uppsala University, SE-75185 Uppsala, Sweden, Uppsala, Sweden","CSlideId":"","ControlKey":"f5cfa98e-3149-489e-8cf4-af55ec3178a7","ControlNumber":"10496","DisclosureBlock":"&nbsp;<b>S. Enroth, <\/b> None..<br><b>M. Moskov, <\/b> None..<br><b>J. Lindberg Hedlund, <\/b> None..<br><b>S. Popova, <\/b> None..<br><b>S. K. G. Forsberg, <\/b> None..<br><b>K. Diamanti, <\/b> None..<br><b>M. Lycke, <\/b> None..<br><b>E. Ivansson, <\/b> None..<br><b>A. Tolf, <\/b> None..<br><b>K. Sundfeldt, <\/b> None..<br><b>K. Stålberg, <\/b> None..<br><b>U. Gyllensten, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10390","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB098","PresenterBiography":null,"PresenterDisplayName":"Mikaela Moskov, MSc","PresenterKey":"0695a880-f986-4f86-961d-5cd921456edc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB098. <b>Deep plasma proteome characterization in two independent clinical cohorts identifies clusters of biomarkers separating benign and malign tumors in women with suspicion of ovarian cancer<\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"<b>Deep plasma proteome characterization in two independent clinical cohorts identifies clusters of biomarkers separating benign and malign tumors in women with suspicion of ovarian cancer<\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-02 Diagnostic biomarkers,,"},{"Key":"Keywords","Value":"NSCLC,Exosomes,Plasma,Targeted therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H. He<\/b><sup>1<\/sup>, J. Milosevic<sup>1<\/sup>, S. Zheng<sup>2<\/sup>; <br\/><sup>1<\/sup>Captis Diagnostics, Pittsburgh, PA, <sup>2<\/sup>Carnegie Mellon University, Pittsburgh, PA","CSlideId":"","ControlKey":"cea50503-5907-45fd-9744-c9893f7bf55f","ControlNumber":"10775","DisclosureBlock":"&nbsp;<b>H. He, <\/b> None..<br><b>J. Milosevic, <\/b> None..<br><b>S. Zheng, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10391","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB099","PresenterBiography":null,"PresenterDisplayName":"Hongzhang (Simon) He, PhD","PresenterKey":"8897076e-6f57-4661-8e59-fe980a44c82f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB099. Identifying actionable genomic alterations in non-small cell lung cancer through the analysis of extracellular vesicles in plasma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identifying actionable genomic alterations in non-small cell lung cancer through the analysis of extracellular vesicles in plasma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-03 Early detection biomarkers,,"},{"Key":"Keywords","Value":"Biomarkers,Early detection,Liquid biopsies,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"V. Gainullin, H. Hwang, L. Hogstrom, K. Arvai, A. Best, M. Gray, M. Kumar, M. Manesse, X. Chen, P. Uren, A. Mazloom, G. Cerqueira, J. Garces, T. M. Beer, A. Mcelhinny, <b>F. Diehl<\/b>; <br\/>EXACT Sciences Corp., Madison, WI","CSlideId":"","ControlKey":"64d553c1-2d73-4a06-baa0-6bc91487fe0a","ControlNumber":"10677","DisclosureBlock":"<b>&nbsp;V. Gainullin, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>H. Hwang, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>L. Hogstrom, <\/b> <br><b>Exct Sciences Corporation<\/b> Employment, Stock. <br><b>K. Arvai, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>A. Best, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>M. Gray, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>M. Kumar, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>M. Manesse, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>X. Chen, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>P. Uren, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>Biora Biosciences<\/b> Stock. <br><b>A. Mazloom, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>G. Cerqueira, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>J. Garces, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>T. M. Beer, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>Arvinas<\/b> Other, Consulting\/advisory role.. <br><b>Salarius Pharmaceuticals<\/b> Stock. <br><b>Osteologic<\/b> Stock. <br><b>Osheru<\/b> Stock. <br><b>Astellas<\/b> Grant\/Contract, Other, Consulting\/advisory role. Research funding through institution.. <br><b>AstraZeneca<\/b> Other, Consulting\/advisory role.. <br><b>Bayer<\/b> Grant\/Contract, Other, Consulting\/advisory role. Research funding through institution.. <br><b>Sanofi<\/b> Other, Consulting\/advisory role.. <br><b>GlaxoSmithKline<\/b> Other, Consulting\/advisory role.. <br><b>Lantheus<\/b> Other, Consulting\/advisory role.. <br><b>Alliance Foundation Trials<\/b> Grant\/Contract, Research funding through institution.. <br><b>Corcept Therapeutics<\/b> Grant\/Contract, Research funding through institution.. <br><b>Freenome<\/b> Grant\/Contract, Research funding through institution.. <br><b>GRAIL<\/b> Grant\/Contract, Research funding through institution.. <br><b>Harpoon Therapeutics<\/b> Grant\/Contract, Research funding through institution.&nbsp;<br><b>A. Mcelhinny, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock. <br><b>F. Diehl, <\/b> <br><b>Exact Sciences Corporation<\/b> Employment, Stock.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10392","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB100","PresenterBiography":null,"PresenterDisplayName":"Frank Diehl, PhD","PresenterKey":"b464f44d-62e3-4f52-a274-9189d96271db","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB100. Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-03 Early detection biomarkers,,"},{"Key":"Keywords","Value":"Cell-free DNA,Liquid Biopsy,Premalignancy,Oral cancers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"N. Swarup<sup>1<\/sup>, J. C. Cheng<sup>2<\/sup>, <b>I. Choi<\/b><sup>1<\/sup>, M. A. Aziz<sup>1<\/sup>, K. Y. P. Liu<sup>3<\/sup>, F. Wei<sup>1<\/sup>, F. Li<sup>1<\/sup>, Y. Kim<sup>1<\/sup>, C. Poh<sup>4<\/sup>, D. T. W. Wong<sup>1<\/sup>; <br\/><sup>1<\/sup>UCLA School of Dentistry, Department of Oral Biology, Los Angeles, CA, <sup>2<\/sup>Stanford Cancer Institute, Palo Alto, CA, <sup>3<\/sup>School of Biomedical Engineering, University of British Columbia Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia Department of Integrative Oncology, BC Cancer Research Institute, British Columbia, BC, Canada, <sup>4<\/sup>Integrative Oncology, BC Cancer Research Institute,  Oral Biological and Medical Sciences, British Columbia, BC, Canada","CSlideId":"","ControlKey":"1f05b48e-0b86-4843-8690-0a08d1bf11cd","ControlNumber":"10688","DisclosureBlock":"&nbsp;<b>N. Swarup, <\/b> None..<br><b>J. C. Cheng, <\/b> None..<br><b>I. Choi, <\/b> None..<br><b>M. A. Aziz, <\/b> None..<br><b>K. Y. P. Liu, <\/b> None..<br><b>F. Wei, <\/b> None..<br><b>F. Li, <\/b> None..<br><b>Y. Kim, <\/b> None..<br><b>C. Poh, <\/b> None.&nbsp;<br><b>D. T. W. Wong, <\/b> <br><b>RNAmeTRIX<\/b> Other, Equity. <br><b>GSK<\/b> Other, Consultant. <br><b>Mars-Wrigley<\/b> Other, Consultant. <br><b>Colgate Palmolive<\/b> Other, Consultant\u000d\u000a.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10394","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB102","PresenterBiography":null,"PresenterDisplayName":"Irene Choi, BS","PresenterKey":"80bc34c3-aab5-4e36-804f-91fa9561c129","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB102. Triaging oral premalignant lesions: Plasma ultrashort cell-free DNA-based liquid biopsy approach","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Triaging oral premalignant lesions: Plasma ultrashort cell-free DNA-based liquid biopsy approach","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies:  Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Cell-free DNA,Methylation,Prognostic model,Biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. Hu<\/b>, B. Tran, S. Li, M. L. Stackpole, W. Zeng, Y. Zhou, A. Melehy, X. Zhou, W. Li, V. Agopian; <br\/>UCLA - University of California Los Angeles, Los Angeles, CA","CSlideId":"","ControlKey":"1433c94b-58c9-45f7-993c-753614f357e4","ControlNumber":"9893","DisclosureBlock":"&nbsp;<b>R. Hu, <\/b> None..<br><b>B. Tran, <\/b> None.&nbsp;<br><b>S. Li, <\/b> <br><b>EarlyDiagnostics Inc.<\/b> Stock Option. <br><b>M. L. Stackpole, <\/b> <br><b>EarlyDiagnostics Inc.<\/b> Employment, Stock Option, Patent. <br><b>W. Zeng, <\/b> <br><b>EarlyDiagnostics Inc.<\/b> Stock, Patent, Other, Consultation. <br><b>Y. Zhou, <\/b> <br><b>EarlyDiagnostics Inc.<\/b> Stock.<br><b>A. Melehy, <\/b> None.&nbsp;<br><b>X. Zhou, <\/b> <br><b>EarlyDiagnostics Inc.<\/b> Stock, Stock Option, Patent. <br><b>W. Li, <\/b> <br><b>EarlyDiagnostics Inc.<\/b> Stock, Stock Option, Travel, Patent, Other, Consultation.<br><b>V. Agopian, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10395","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB103","PresenterBiography":null,"PresenterDisplayName":"Ran Hu, B Eng","PresenterKey":"58cac1d6-c958-4bd1-8cb8-559d3f73836b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB103. Cell-free DNA methylation as a noninvasive prognostic biomarker in hepatocellular carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Cell-free DNA methylation as a noninvasive prognostic biomarker in hepatocellular carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies:  Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Circulating tumor DNA,Efficacy,Phase I,Predictive biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"L. Belcaid<sup>1<\/sup>, S. Cousin<sup>2<\/sup>, A. Bayle<sup>3<\/sup>, M. Alame<sup>2<\/sup>, E. Rouleau<sup>3<\/sup>, L. Blouin<sup>2<\/sup>, L. Lacroix<sup>3<\/sup>, D. Vasseur<sup>3<\/sup>, M. Brunet<sup>2<\/sup>, S. Taleb<sup>3<\/sup>, I. Soubeyran<sup>2<\/sup>, V. Debien<sup>2<\/sup>, E. Angeli<sup>2<\/sup>, C. Massard<sup>3<\/sup>, <b>A. Italiano<\/b><sup>2<\/sup>; <br\/><sup>1<\/sup>University of Danemark, Copenhague, Denmark, <sup>2<\/sup>Institute Bergonié, Bordeaux, France, <sup>3<\/sup>Gustave Roussy, Villejuif, France","CSlideId":"","ControlKey":"ad828e18-37b7-407e-ac95-abe77db5e4de","ControlNumber":"10543","DisclosureBlock":"&nbsp;<b>L. Belcaid, <\/b> None..<br><b>S. Cousin, <\/b> None..<br><b>A. Bayle, <\/b> None..<br><b>M. Alame, <\/b> None..<br><b>E. Rouleau, <\/b> None..<br><b>L. Blouin, <\/b> None..<br><b>L. Lacroix, <\/b> None..<br><b>D. Vasseur, <\/b> None..<br><b>M. Brunet, <\/b> None..<br><b>S. Taleb, <\/b> None..<br><b>I. Soubeyran, <\/b> None..<br><b>V. Debien, <\/b> None..<br><b>E. Angeli, <\/b> None..<br><b>C. Massard, <\/b> None.&nbsp;<br><b>A. Italiano, <\/b> <br><b>BAYER<\/b> Grant\/Contract. <br><b>BMS<\/b> Grant\/Contract. <br><b>MSD<\/b> Grant\/Contract. <br><b>MERCK<\/b> Grant\/Contract. <br><b>ASTRAZENECA<\/b> Grant\/Contract.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10396","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB104","PresenterBiography":null,"PresenterDisplayName":"Antoine Italiano, MD;PhD","PresenterKey":"b2437d6d-3857-4a75-bae3-60a267fe9e51","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB104. Tumor fraction as a predictive factor of outcome in patients referred for oncology early phase clinical trials: Analyses of two precision medicine studies","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Tumor fraction as a predictive factor of outcome in patients referred for oncology early phase clinical trials: Analyses of two precision medicine studies","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies:  Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Biomarkers,Urine,Bladder cancer,Liquid biopsies,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Nikkola<\/b><sup>1<\/sup>, L. Ryyppö<sup>2<\/sup>, J. Vuorinen<sup>2<\/sup>, H. Kallio<sup>2<\/sup>, H. Selin<sup>2<\/sup>, P. Jämsä<sup>1<\/sup>, J. Åkerla<sup>1<\/sup>, T. Pekkarinen<sup>1<\/sup>, A. Kaipia<sup>1<\/sup>, M. Nykter<sup>2<\/sup>, T. Veitonmäki<sup>1<\/sup>, M. Annala<sup>2<\/sup>; <br\/><sup>1<\/sup>Department of Urology, Tampere University Hospital, Tampere, Finland, <sup>2<\/sup>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland","CSlideId":"","ControlKey":"f92c22b3-7159-4eb0-ad07-c3ef7bcb078b","ControlNumber":"10462","DisclosureBlock":"&nbsp;<b>J. Nikkola, <\/b> None..<br><b>L. Ryyppö, <\/b> None.&nbsp;<br><b>J. Vuorinen, <\/b> <br><b>Fluivia<\/b> Other Business Ownership.<br><b>H. Kallio, <\/b> None..<br><b>H. Selin, <\/b> None..<br><b>P. Jämsä, <\/b> None..<br><b>J. Åkerla, <\/b> None..<br><b>T. Pekkarinen, <\/b> None..<br><b>A. Kaipia, <\/b> None..<br><b>M. Nykter, <\/b> None..<br><b>T. Veitonmäki, <\/b> None.&nbsp;<br><b>M. Annala, <\/b> <br><b>Fluivia<\/b> Other Business Ownership.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10397","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB105","PresenterBiography":null,"PresenterDisplayName":"Jussi Nikkola","PresenterKey":"ba64733b-0cf4-456c-a052-02b7668af2f9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB105. Sensitive urothelial cancer detection via high volume urine DNA analysis","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Sensitive urothelial cancer detection via high volume urine DNA analysis","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies:  Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Circulating cell-free DNA,Liquid biopsies,Cancer detection,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>F. Li<\/b><sup>1<\/sup>, F. Wei<sup>1<\/sup>, H.-J. He<sup>2<\/sup>, C.-C. Lin<sup>3<\/sup>, S.-C. Yang<sup>3<\/sup>, A. W. Huang<sup>3<\/sup>, C. Tang<sup>4<\/sup>, Y. Kim<sup>1<\/sup>, D. T. W. Wong<sup>1<\/sup>; <br\/><sup>1<\/sup>University of California Los Angeles, Los Angeles, CA, <sup>2<\/sup>National Institute of Standards and Technology, Gaithersburg, MD, <sup>3<\/sup>National Cheng Kung University Hospital, Tainan, Taiwan, <sup>4<\/sup>AIONco Inc., Menlo Park, CA","CSlideId":"","ControlKey":"9333ccb2-e39f-4853-a836-925ecf1308a0","ControlNumber":"9841","DisclosureBlock":"&nbsp;<b>F. Li, <\/b> None.&nbsp;<br><b>F. Wei, <\/b> <br><b>EZ Life Bio<\/b> Stock.<br><b>H. He, <\/b> None..<br><b>C. Lin, <\/b> None..<br><b>S. Yang, <\/b> None..<br><b>A. W. Huang, <\/b> None.&nbsp;<br><b>C. Tang, <\/b> <br><b>AIONco Inc.<\/b> Employment.<br><b>Y. Kim, <\/b> None.&nbsp;<br><b>D. T. W. Wong, <\/b> <br><b>Liquid Diagnostics<\/b> Stock. <br><b>AIOnco<\/b> Stock, Grant\/Contract. <br><b>NIH<\/b> Grant\/Contract. <br><b>American Cancer Society<\/b> Grant\/Contract.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10398","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB106","PresenterBiography":null,"PresenterDisplayName":"Feng Li, PhD","PresenterKey":"4156fb92-9f46-49ca-ad00-9f596bff23e0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB106. Ultra-short ctDNA: A new paradigm for ctDNA liquid biopsy","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Ultra-short ctDNA: A new paradigm for ctDNA liquid biopsy","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies:  Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Circulating tumor DNA,Liquid biopsies,NSCLC,Pembrolizumab,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Jair Bar<sup>1<\/sup>, Emilio Esteban<sup>2<\/sup>, Delvys Rodríguez-Abreu<sup>3<\/sup>, Santiago Ponce-Aix<sup>4<\/sup>, Zsuzsanna Szalai<sup>5<\/sup>, Enriqueta Felip<sup>6<\/sup>, Maya Gottfried<sup>7<\/sup>, Mariano Provencio Pulla<sup>8<\/sup>, Andrew Robinson<sup>9<\/sup>, Andrea Fülöp<sup>10<\/sup>, Suman Bannur Rao<sup>11<\/sup>, D. Ross Camidge<sup>12<\/sup>, Giovanna Speranza<sup>13<\/sup>, Nathan Hunkapiller<sup>14<\/sup>, Robert McDaniel<sup>14<\/sup>, Byoungsok Jung<sup>14<\/sup>, David Burkhardt<sup>14<\/sup>, Ruth Mauntz<sup>14<\/sup>, Cai Chen<sup>15<\/sup>, Carol Pena<sup>15<\/sup>, Razvan Cristescu<sup>15<\/sup>, <b>Elisha  J.  Dettman<\/b><sup>15<\/sup>, Steven  M.  Townson<sup>15<\/sup>, Julie Kobie<sup>15<\/sup>, Tibor Cs&#337;szi<sup>16<\/sup><br><br\/><sup>1<\/sup>Sheba Medical Center–Tel Hashomer and Tel-Aviv University Medical School, Ramat Gan, Israel,<sup>2<\/sup>Central University Hospital of Asturias, Oviedo, Spain,<sup>3<\/sup>3Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain,<sup>4<\/sup>Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and CIBERONC, Madrid, Spain,<sup>5<\/sup>Petz Aladar Megyei Oktato Korhaz, Budapest, Hungary,<sup>6<\/sup>Vall d’Hebron University, Vall d’Hebron Institute of Oncology (VHIO), Bracelona, Spain,<sup>7<\/sup>Meir Medical Center, Kfar-Saba, Israel,<sup>8<\/sup>Hospital Universitario Puerta de Hierro, Madrid, Spain,<sup>9<\/sup>Queen's University, Kingston, ON, Canada,<sup>10<\/sup>Országos Korányi Pulmonológiai Intézet, Budapest, Hungary,<sup>11<\/sup>Ascension Saint Agnes Hospital, Baltimore, MD,<sup>12<\/sup>University of Colorado School of Medicine, Aurora, CO,<sup>13<\/sup>Centre Integré de Cancérologie de la Montérégie, Université de Sherbrooke, Greenfield Park, QC, Canada,<sup>14<\/sup>GRAIL, Menlo Park, CA,<sup>15<\/sup>Merck & Co., Inc., Rahway, NJ,<sup>16<\/sup>Jász-Nagykun-Szolnok County Hospital, Szolnok, Hungary","CSlideId":"","ControlKey":"6854a48e-09b9-4807-88d3-5c6d0997d931","ControlNumber":"10440","DisclosureBlock":"<b>&nbsp;J. Bar, <\/b> <br><b>AbbVie<\/b> Grant\/Contract, Other, Advisory Board (Personal); Research Grant (Institutional). <br><b>Amgen<\/b> Other, Advisory Board (Personal). <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Advisory Board (Personal); Research Grant (Institutional). <br><b>Bayer<\/b> Other, Advisory Board (Personal). <br><b>MSD<\/b> Grant\/Contract, Other, Advisory Board (Personal); Research Grant (Institutional). <br><b>Merck-Serono<\/b> Other, Advisory Board (Personal). <br><b>Roche<\/b> Grant\/Contract, Other, Advisory Board (Personal); Research Grant (Institutional). <br><b>Takeda<\/b> Other, Advisory Board (Personal). <br><b>BMS<\/b> Other, Invited Speaker. <br><b>Medison<\/b> Invited Speaker. <br><b>Pfizer<\/b> Other, Invited Speaker. <br><b>Immunai<\/b> Grant\/Contract, Research Grant (institutional). <br><b>OncoHost<\/b> Other, Research Grant (institutional).<br><b>E. Esteban, <\/b> None.&nbsp;<br><b>D. Rodríguez-Abreu, <\/b> <br><b>Roche\/Genentech, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp and Dohme, Merck Serono, Eli Lilly, Gilead, Sanofi, Regeneron, Incyte, Pfizer, Takeda and Novartis<\/b> Other, Received personal fees\/honoraria for consultancy\/ Advisory role and lectures. <br><b>Roche, Bristol-Myers Squibb, Merck Sharp and Dohme, Sanofi, Regeneron and Novartis<\/b> Travel.<br><b>S. Ponce-Aix, <\/b> None..<br><b>Z. Szalai, <\/b> None.&nbsp;<br><b>E. Felip, <\/b> <br><b>ABBVIE, AMGEN, ASTRA ZENECA, BAYER, BEIGENE, BOEHRINGER INGELHEIM, BRISTOL MYERS SQUIBB, ELI LILLY, F. HOFFMANN-LA ROCHE, GILEAD, GLAXO SMITH KLINE, JANSSEN, MERCK SERONO, MERCK SHARP & DOHME, NOVART<\/b> Other, Advisory Board. <br><b>AMGEN, ASTRA ZENECA, BRISTOL MYERS SQUIBB, DAIICHI SANKYO, ELI LILLY, F. HOFFMANN – LA ROCHE, GENENTECH, JANSSEN, MEDICAL TRENDS, MEDSCAPE, MERCK SERONO, MERCK SHARP & DOHME, PEERVOICE, PFIZER, SANOF<\/b> Other, Speakers Bureau. <br><b>GRIFOLS<\/b> Other, INDEPENDENT MEMBER OF THE BOARD.<br><b>M. Gottfried, <\/b> None.&nbsp;<br><b>M. Provencio Pulla, <\/b> <br><b>MSD<\/b> Grant\/Contract, Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional). <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional), Support for attending meetings\u000d\u000aand\/or travel (Institutional). <br><b>Roche<\/b> Grant\/Contract, Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional). <br><b>Boehringer Ingelheim<\/b> Grant\/Contract, Travel, Support for attending meetings\u000d\u000aand\/or travel (Institutional). <br><b>Takeda<\/b> Grant\/Contract, Travel, Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional), Support for attending meetings\u000d\u000aand\/or travel (Institutional). <br><b>BMS<\/b> Travel, Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional), Support for attending meetings\u000d\u000aand\/or travel (Institutional). <br><b>Eli Lily<\/b> Travel, Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional), Support for attending meetings\u000d\u000aand\/or travel (Institutional). <br><b>F Hoffman-La Roche<\/b> Travel, Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional), Support for attending meetings\u000d\u000aand\/or travel (Institutional). <br><b>Janssen<\/b> Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional). <br><b>Pfizer<\/b> Other, Consulting Fees, Speakers Bureau, Training (Personal & Institutional). <br><b>Phierre Fabre Pharmaceuticals<\/b> Travel, Support for attending meetings\u000d\u000aand\/or travel (Institutional). <br><b>A. Robinson, <\/b> <br><b>Merck<\/b> Other, Speaker Fees, Advisory Board. <br><b>Astra-Zeneca<\/b> Other, Speaker Fees, Advisory Board. <br><b>BMS<\/b> Other, Advisory Board.<br><b>A. Fülöp, <\/b> None.&nbsp;<br><b>S. Rao, <\/b> <br><b>Astra-Zeneca<\/b> Other, Speakers Bureau. <br><b>D. Camidge, <\/b> <br><b>Abbvie, Anheart, Appollomics, AstraZeneca, Aveo, Beigene, BMS, Coherus, Eli Lilly, Gilead, Hengrui, Imagene, Immunocore, Janssen, Lianbio, Merck KGa, Mirati, Nalo, Newsoara, Nextcutre, Prelude, Roche<\/b> Other, Advisory Role. <br><b>Sanofi, Seattle Genetics, Sutro, Takeda, Valence, Xencor, AstraZeneca\/Daiichi, Dizal, EMD Serono, Elevation, Hummingbird, Medtronic, Mersana, Onkure, Regeneron, Theseus, Xcovery<\/b> Other, Advisory Role. <br><b>Bio-Thera, Blueprint, Helsinn, Kestrel, Nuvalent, Puma, Ribon, Roche\/Genetech, Turning Point<\/b> Other, Advisory Role. <br><b>Abbie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Nuvalent, Pfizer, Phosplatin, Psioxus, rain, Roche\/Genetech, Seattle Genetics, Takeda, Turning Point, Verastem<\/b> Other, Company Sponsored trials at institution (PI Roles).<br><b>G. Speranza, <\/b> None.&nbsp;<br><b>N. Hunkapiller, <\/b> <br><b>GRAIL<\/b> Employment, Stock, Ownership Interest, Leadership Role. <br><b>Curve Biosciences<\/b> Employment, Stock, Other, Officer, Member of the board of Directors, Ownership Interest, Leadership Role. <br><b>Droplet Biosciences<\/b> Stock, Advisory Board, Ownership Interest, Advisory Role. <br><b>R. McDaniel, <\/b> <br><b>GRAIL<\/b> Employment. <br><b>B. Jung, <\/b> <br><b>Illumina<\/b> Stock. <br><b>D. Burkhardt, <\/b> <br><b>GRAIL<\/b> Employment. <br><b>Illumina<\/b> Stock. <br><b>R. Mauntz, <\/b> <br><b>GRAIL<\/b> Employment. <br><b>Illumina<\/b> Employment, Stock. <br><b>C. Chen, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Stock. <br><b>C. Pena, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Stock. <br><b>R. Cristescu, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Stock. <br><b>E. J. Dettman, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Stock. <br><b>S. M. Townson, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Stock, Other, Project Lead, Proprietary information, leadership role. <br><b>J. Kobie, <\/b> <br><b>Merck & Co, Inc<\/b> Employment, Stock.<br><b>T. Cs&#337;szi, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10399","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB107","PresenterBiography":null,"PresenterDisplayName":"Elisha Dettman, PhD","PresenterKey":"4bc3bd1a-8ef4-4ae1-97a5-b4944c46fa42","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB107. Association of circulating free DNA (cfDNA) maximum variant allele frequency (mVAF) levels with clinical outcomes in patients (pts) with metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with pembrolizumab (pembro) + chemotherapy (chemo) in the phase 2 KEYNOTE-782 trial","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Association of circulating free DNA (cfDNA) maximum variant allele frequency (mVAF) levels with clinical outcomes in patients (pts) with metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with pembrolizumab (pembro) + chemotherapy (chemo) in the phase 2 KEYNOTE-782 trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies:  Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Circulating cell-free DNA,Machine learning,Biomarkers,Lung adenocarcinoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. C. Hyun<\/b><sup>1<\/sup>, S. H. Yip<sup>1<\/sup>, N. Swarup<sup>2<\/sup>, R. Ramamurthy<sup>1<\/sup>, J. C. Cheng<sup>2<\/sup>, I. Choi<sup>2<\/sup>, E. Wong<sup>1<\/sup>, A. Arora<sup>2<\/sup>, D. Aberle<sup>2<\/sup>, D. T. W. Wong<sup>2<\/sup>, C. Y. Tang<sup>1<\/sup>; <br\/><sup>1<\/sup>AiOnco, Inc., Menlo Park, CA, <sup>2<\/sup>University of California Los Angeles, Los Angeles, CA","CSlideId":"","ControlKey":"55ce2646-6c55-49da-917e-cc6582cca5df","ControlNumber":"10572","DisclosureBlock":"<b>&nbsp;J. C. Hyun, <\/b> <br><b>AiOnco<\/b> Employment, Patent. <br><b>S. H. Yip, <\/b> <br><b>AiOnco<\/b> Employment, Patent.<br><b>N. Swarup, <\/b> None.&nbsp;<br><b>R. Ramamurthy, <\/b> <br><b>AiOnco<\/b> Employment, Patent.<br><b>J. C. Cheng, <\/b> None..<br><b>I. Choi, <\/b> None.&nbsp;<br><b>E. Wong, <\/b> <br><b>AiOnco<\/b> Employment, Patent.<br><b>A. Arora, <\/b> None..<br><b>D. Aberle, <\/b> None.&nbsp;<br><b>D. T. W. Wong, <\/b> <br><b>Liquid Diagnostics<\/b> Stock. <br><b>AiOnco<\/b> Stock, Grant\/Contract. <br><b>NIH<\/b> Grant\/Contract. <br><b>American Cancer Society<\/b> Grant\/Contract. <br><b>C. Y. Tang, <\/b> <br><b>AiOnco<\/b> Employment, Stock, Patent.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10400","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB108","PresenterBiography":null,"PresenterDisplayName":"Jason Hyun","PresenterKey":"faffd6f2-522e-4cdc-8403-99b2e45dab08","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB108. Specific plasma DNA end-motifs distinguish patients with lung adenocarcinoma versus benign nodules","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Specific plasma DNA end-motifs distinguish patients with lung adenocarcinoma versus benign nodules","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies:  Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Cancer detection,Colon cancer,Liquid biopsies,Methylation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Wu<sup>1<\/sup>, Y. Tong<sup>2<\/sup>, H. Zhang<sup>3<\/sup>, Y. Li<sup>3<\/sup>, M. Li<sup>4<\/sup>, L. Qiu<sup>5<\/sup>, W. Liu<sup>6<\/sup>, S. Mei<sup>2<\/sup>, Y. Mao<sup>7<\/sup>, Y. Cao<sup>7<\/sup>, C. Su<sup>7<\/sup>, W. Yu<sup>8<\/sup>, J. Wang<sup>9<\/sup>, T. Wang<sup>9<\/sup>, Z. Zhu<sup>5<\/sup>, <b>D. Yu<\/b><sup>9<\/sup>; <br\/><sup>1<\/sup>Xiaolan People's Hospital, Zhognshan, China, <sup>2<\/sup>Renmin Hospital of Wuhan University, Wuhan, China, <sup>3<\/sup>The Second People’s Hospital of Shenzhen, Shenzhen, China, <sup>4<\/sup>Renmin Hospital of Wuhan University,, Wuhan, China, <sup>5<\/sup>The Second Affiliated Hospital of Hainan Medical University, Haikou, China, <sup>6<\/sup>The Second People’s Hospital of Shenzhen, BShenzhen, China, <sup>7<\/sup>USK Bioscience, Co., Ltd, Shenzhen, China, <sup>8<\/sup>caiyan.su@uskbio.com, Shenzhen, China, <sup>9<\/sup>Youjiang Medical University For Nationalities, Baise, China","CSlideId":"","ControlKey":"ba437db1-8434-4ce0-bed0-4e2a0195aec7","ControlNumber":"10515","DisclosureBlock":"&nbsp;<b>Y. Wu, <\/b> None..<br><b>Y. Tong, <\/b> None..<br><b>H. Zhang, <\/b> None..<br><b>Y. Li, <\/b> None..<br><b>M. Li, <\/b> None..<br><b>L. Qiu, <\/b> None..<br><b>W. Liu, <\/b> None..<br><b>S. Mei, <\/b> None..<br><b>Y. Mao, <\/b> None..<br><b>Y. Cao, <\/b> None..<br><b>C. Su, <\/b> None..<br><b>W. Yu, <\/b> None..<br><b>J. Wang, <\/b> None..<br><b>T. Wang, <\/b> None..<br><b>Z. Zhu, <\/b> None..<br><b>D. Yu, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10401","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB109","PresenterBiography":null,"PresenterDisplayName":"Youming Wu, MD","PresenterKey":"acfe7211-5da1-44eb-a5ec-ee8cb49051f8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB109. Detection of high grade intraepithelial neoplasia in colorectal cancer using a new blood-based multiplex septin9 methylation assay","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Detection of high grade intraepithelial neoplasia in colorectal cancer using a new blood-based multiplex septin9 methylation assay","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL01-05 Liquid biopsies: Circulating tumor cells,,"},{"Key":"Keywords","Value":"Biomarkers,Circulating tumor cells,Prostate cancer,Prostate-specific membrane antigen (PSMA),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"H. Cho<sup>1<\/sup>, S.-S. Byun<sup>2<\/sup>, N.-H. Son<sup>3<\/sup>, J. Chung<sup>4<\/sup>, W. Seo<sup>4<\/sup>, C. Lee<sup>4<\/sup>, T. Morgan<sup>5<\/sup>, K.-H. Han<sup>1<\/sup>, <b>J.-S. Chung<\/b><sup>6<\/sup>; <br\/><sup>1<\/sup>Department of Nanoscience and Engineering Center for Nano Manufacturing, Inje University, Kimhae, Korea, Republic of, <sup>2<\/sup>Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of, <sup>3<\/sup>Department of Statistics, Keimyung University, Daegu, Korea, Republic of, <sup>4<\/sup>Department of Urology, Inje University Pusan Paik Hospital, Busan, Korea, Republic of, <sup>5<\/sup>Department of Urology, University of Michigan, Ann Arbor, MI, <sup>6<\/sup>Department of Urology, Inje University Haeundae Paik Hospital, Busan, Korea, Republic of","CSlideId":"","ControlKey":"c0d83339-25aa-4b2c-af06-d95cb2ff882f","ControlNumber":"9765","DisclosureBlock":"&nbsp;<b>H. Cho, <\/b> None..<br><b>S. Byun, <\/b> None..<br><b>N. Son, <\/b> None..<br><b>J. Chung, <\/b> None..<br><b>W. Seo, <\/b> None..<br><b>C. Lee, <\/b> None..<br><b>T. Morgan, <\/b> None..<br><b>K. Han, <\/b> None..<br><b>J. Chung, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10402","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB110","PresenterBiography":null,"PresenterDisplayName":"Jae-Seung Chung, D Phil;MD","PresenterKey":"212001d6-1ce8-40b9-a7b6-60caf40e879a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB110. Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in various stages of prostate cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in various stages of prostate cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL13-02 Cytogenetics and clinical molecular genetics,,"},{"Key":"Keywords","Value":"Colorectal cancer,Telomeres,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>P. Hanák<\/b>; <br\/>Institute of Experimental Medicine, AVCR, Praha, Czech Republic","CSlideId":"","ControlKey":"fea84ca3-c22a-482a-9d37-816d8335a7a9","ControlNumber":"10364","DisclosureBlock":"&nbsp;<b>P. Hanák, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11669","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB111","PresenterBiography":null,"PresenterDisplayName":"Petr Hanak, D Phil,Dr Rer Nat","PresenterKey":"2f77922b-6bf3-4f99-9356-3fdff80f4abe","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB111. CORSA study - Telomere length measurement of 5371 Austrian colorectal cancer and adenoma patients and healthy controls: Relationships to tumor stage, course of disease and to clinical, life style and health parameters","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"594","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Clinical Research 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"CORSA study - Telomere length measurement of 5371 Austrian colorectal cancer and adenoma patients and healthy controls: Relationships to tumor stage, course of disease and to clinical, life style and health parameters","Topics":null,"cSlideId":""}]